Well, it's ASCO time, and I'm back with a video on SHINE.

Shine, the randomized control trial that shows you can shine a piece of, well, you can shine about anything.

This is going to be part of my ASCO series.

So there's going to be a number of papers coming out, I think, in the New England Journal of Medicine and other places.

I'm going to try to cover the majority of the papers, because I think those are the hardest hitting abstracts and also the ones where I get the most information to read. And today it's Shine.

We're kicking off Saturday morning with Shine. Shine is a pretty, pretty bad randomized control

trial. It's so bad that I really wonder why it was published in the England Journal. It's not

practice changing. It shouldn't have been selected. People should have pointed out these

concerns. I'm going to run you through them. What is this randomized control trial? Well, we all

know mantle cell lymphoma, a particular type of lymphoma that has sort of a range of

presentations from a very indolent sort of leukemic form to a blastoid and very

aggressive form. And there are a number of different treatments for mantle cell lymphoma.

There is some agreement that Bendamostein retuxin had a longer progression-free survival than

R. Chopp, based on the Rommel study many years ago in indolent lymphomas. And that has been

sort of a preferred go-to

regimen. There are meta-analyses that suggest there may be a benefit from two years of

additional maintenance rituxin. I think one of my colleagues, Talal Hillol is the author of that

study, and enters the new study. This is the shine study, where we take bendamustine retuxin,

and we randomize you to the addition of placebo or ibrutinib.

Now, many of us remember, and I remember because I was a fellow at the time, when ibup

entered the market for mantle cell lymphoma. The year was 2013. We had the previous

Ash in 2012 seen the results of ibrutinup in the phase two study by Wang and colleagues.

...